Loading...
XNAS
ESPR
Market cap661mUSD
Jul 09, Last price  
3.19USD
1D
0.00%
1Q
47.00%
Jan 2017
-74.52%
IPO
-78.00%
Name

Esperion Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:ESPR chart
P/E
—
P/S
1.65
EPS
—
Div Yield, %
—
Shrs. gr., 5y
49.89%
Rev. gr., 5y
12.12%
Revenues
403m
+21.31%
02,00000004,977,012,0000000184,474,000148,364,000227,547,00078,447,00075,475,000116,334,000332,314,000403,135,000
Net income
-23m
L-56.17%
-10,670,184-27,576,000-24,931,000-28,726,000-10,817,341-11,741,736-26,088,133-36,375,000-49,784,000-74,978,000-166,988,000-201,810,000-97,165,000-143,551,000-269,108,000-233,659,000-209,248,000-51,745,000-22,682,000
CFO
-13m
L-44.65%
-7,852,572-17,954,000-22,767,000-26,564,000-9,068,725-10,808,567-18,113,361-32,021,000-38,156,000-47,730,000-131,302,000-148,638,000-70,341,000-85,177,000-263,809,000-174,827,000-135,487,000-23,654,000-13,093,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Esperion Therapeutics, Inc. operates as a pharmaceutical company primarily focused on developing and commercializing medications designed to manage elevated low-density lipoprotein (LDL) cholesterol levels in patients. Its flagship pharmaceutical products include NEXLETOL (bempedoic acid) and NEXLIZET (a combination of bempedoic acid and ezetimibe) in tablet form. These treatments are prescribed for individuals suffering from atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH). Additionally, Esperion has established strategic licensing and collaborative partnerships with Daiichi Sankyo Europe GmbH and Serometrix to obtain rights to an oral, small molecule PCSK9 inhibitor program. The company was founded in 2008 and its principal offices are located in Ann Arbor, Michigan.
URL
https://www.esperion.com/
IPO date
Jun 24, 2013
Employees
199
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT